Qingxiu Huang1,2,3, Jianbo Li1,2, Naya Huang1,2, Xi Xia1,2, Yagui Qiu1,2, Zhong Zhong1,2, Zhenchuan Lin1,2,4, Xiaowen Huang3, Dihua Zhang1,2, Fengxian Huang1,2. 1. Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 2. NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China. 3. Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, China. 4. Department of Nephrology, Kidney and Urology Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
Abstract
OBJECTIVE: End-stage kidney disease (ESKD) patients have a higher risk of antibiotic-associated encephalopathy (AAE) than other patients. We aimed to evaluate the prevalence, risk factors and outcomes of AAE in ESKD patients. METHOD: A retrospective study of ESKD patients treated with intravenous antibiotics in our hospital from Jan. 1, 2006, to Dec. 31, 2015 was performed. AAE was diagnosed by the modified Delphi method. Control individuals were randomly selected from the remaining patients who did not exhibit neurologic symptoms. Logistic regression analysis was used to identify risk factors for AAE as well as the association between AAE and outcome. RESULT: A total of 2104 patients were included in the study. The prevalence of AAE in our study was 4.4% (92/2104). The multivariate logistic regression analysis revealed that anuria (OR = 8.04, 95% CI: 4.13-15.65, p < 0.001), history of central nervous system disorder (OR = 3.03, 95% CI: 1.21-7.56, p = 0.018) and hypoalbuminemia (OR= 1.87, 95% CI: 1.01-3.47, p = 0.046) were independent factors associated with AAE in ESKD patients. After adjustment for confounders, AAE was associated with composite outcomes of in-hospital mortality and treatment withdrawal (OR = 4.36, 95% CI: 2.09-9.10, p < 0.001). CONCLUSION: The prevalence of AAE was 4.4% in ESKD patients and varied among different antibiotics. Anuria, history of central nervous system disorder and hypoalbuminemia were associated with AAE in ESKD patients. AAE is associated with worse outcomes in ESKD patients.
OBJECTIVE: End-stage kidney disease (ESKD) patients have a higher risk of antibiotic-associated encephalopathy (AAE) than other patients. We aimed to evaluate the prevalence, risk factors and outcomes of AAE in ESKD patients. METHOD: A retrospective study of ESKD patients treated with intravenous antibiotics in our hospital from Jan. 1, 2006, to Dec. 31, 2015 was performed. AAE was diagnosed by the modified Delphi method. Control individuals were randomly selected from the remaining patients who did not exhibit neurologic symptoms. Logistic regression analysis was used to identify risk factors for AAE as well as the association between AAE and outcome. RESULT: A total of 2104 patients were included in the study. The prevalence of AAE in our study was 4.4% (92/2104). The multivariate logistic regression analysis revealed that anuria (OR = 8.04, 95% CI: 4.13-15.65, p < 0.001), history of central nervous system disorder (OR = 3.03, 95% CI: 1.21-7.56, p = 0.018) and hypoalbuminemia (OR= 1.87, 95% CI: 1.01-3.47, p = 0.046) were independent factors associated with AAE in ESKD patients. After adjustment for confounders, AAE was associated with composite outcomes of in-hospital mortality and treatment withdrawal (OR = 4.36, 95% CI: 2.09-9.10, p < 0.001). CONCLUSION: The prevalence of AAE was 4.4% in ESKD patients and varied among different antibiotics. Anuria, history of central nervous system disorder and hypoalbuminemia were associated with AAE in ESKD patients. AAE is associated with worse outcomes in ESKD patients.
Authors: Erik Lager; Pierre Andersson; Jakob Nilsson; Ingrid Pettersson; Elsebet Østergaard Nielsen; Mogens Nielsen; Olov Sterner; Tommy Liljefors Journal: J Med Chem Date: 2006-04-20 Impact factor: 7.446
Authors: Tony Velkov; Chongshan Dai; Giuseppe D Ciccotosto; Roberto Cappai; Daniel Hoyer; Jian Li Journal: Pharmacol Ther Date: 2017-07-25 Impact factor: 12.310
Authors: Douglas L Leslie; Ying Zhang; Theodore R Holford; Sidney T Bogardus; Linda S Leo-Summers; Sharon K Inouye Journal: Arch Intern Med Date: 2005-07-25
Authors: F R Bruniera; F M Ferreira; L R M Saviolli; M R Bacci; D Feder; M da Luz Gonçalves Pedreira; M A Sorgini Peterlini; L A Azzalis; V B Campos Junqueira; F L A Fonseca Journal: Eur Rev Med Pharmacol Sci Date: 2015-02 Impact factor: 3.507
Authors: E Wesley Ely; Ayumi Shintani; Brenda Truman; Theodore Speroff; Sharon M Gordon; Frank E Harrell; Sharon K Inouye; Gordon R Bernard; Robert S Dittus Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Shamik Bhattacharyya; R Ryan Darby; Pooja Raibagkar; L Nicolas Gonzalez Castro; Aaron L Berkowitz Journal: Neurology Date: 2016-02-17 Impact factor: 9.910